Archives: Partners

The Human Genetics department of Radboud University Medical Center (Radboudumc), with over 430 employees, is an internationally top-ranked department and the largest genetics research, clinical diagnostics, and genetic counseling center in Europe. Research is performed by 26 Principal Investigator groups, with genetic/genomic neuroscience as one of the most important research focuses. The neuroscience work of the Human Genetics department is embedded in the Donders Institute for Brain, Cognition and Behaviour (DI), a world-renowned neuroscience institute. Over 600 researchers work at the Donders Institute on unravelling the mechanisms underlying brain function in health and disease, including expertise in neurodevelopmental and neurodegeneration-related brain disorders. The Radboudumc and DI team includes world-class researchers and opinion leaders in the field of human molecular genetics and imaging. Among those, Professor Barbara Franke (Departments of Human Genetics & Psychiatry) is a renowned expert in the biological underpinnings of psychiatric disorders. Her research focus lies on gene-finding as well as the evaluation of gene-to-disease biological pathways through imaging genetics, animal models, and bioinformatic modelling. As a professor of Molecular Psychiatry, she has appointments at the Human Genetics department as well as the Psychiatry department of RUMC, which provides her with a close view on the evaluation and implementation of new treatments into clinical practice.

In PRISM 2, Radboudumc contributes to WP2 – Data management, sustainability, and analysis.

P1vital® is an innovative Clinical Research Organization specializing in experimental medicine for Central Nervous System (CNS) disorders. We develop and deploy CNS efficacy biomarkers in schizophrenia, cognitive disorders, depression and anxiety, eating disorders, and obesity – with the aim of instigating innovative approaches to, and accelerating, drug research and development. P1vital Products Ltd, affiliated with P1vital Ltd, specialises in providing digital solutions for the pharmaceutical and healthcare sectors to improve the quality, compliance, timeliness and accessibility of eCOA, ePRO, and digital biomarker data collection. Our team has extensive expertise in all aspects of CNS drug discovery and development, including regulatory and compliance expertise. We are also skilled in running multi-centred academic, behavioural, and imaging clinical studies (across all phases) that require subjects with unique phenotypes. We have a strong track record of collaborating with internationally renowned opinion leaders in psychiatry and neuroscience, linked through University hospitals and clinical research facilities worldwide.

P1vital Ltd led the clinical project management of the original PRISM project and will continue this legacy in leading WP03 (Clinical study implementation and operations) for the PRISM 2 project. We also contribute to WP2 (Data management, sustainability, and analysis) and WP5 (Ethics and engagement with regulatory groups, agencies, and other stakeholders).

Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Around 52,000 employees serve more than 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.

At Boehringer Ingelheim Mental Health, we are redefining mental health to enable people to thrive. We link behavior to the underlying neurobiology to develop targeted therapies that can ease the burden of these conditions, not just the symptoms. By combining traditional treatment approaches with new and innovative approaches and technologies, we will enable those with mental health conditions to create more meaningful connections to their lives, loved ones and society.

We are the project leader of PRISM 2 and therefore actively involved in all work packages, especially WP1 (project management & governance). Together with the project coordinator, we oversee the progress of all work packages.

The University of Groningen (RUG) has an international reputation as a dynamic and innovative center of higher education offering high-quality teaching and research. Balanced study and career paths in a wide variety of disciplines encourage the 30,000 students and researchers to develop their own individual talents. Belonging to the best research universities in Europe and joining forces with prestigious partner universities and networks, RUG is truly an international place of knowledge. The Groningen Institute of Evolutionary Life Sciences (GELIFES) fills a special niche in the field of life sciences that not only covers mechanistic, evolutionary and ecological approaches, but also specifically aims at the integration of these fields to provide a full understanding of fundamental biological processes.

RUG contributes to work packages on data analyses, management and sustainability (WP2), clinical study implementation and operations (WP3), ethics and engagement with regulatory groups, agencies and other stakeholders (WP5) and dissemination, communication, exploitation and training (WP6). Those tasks are required to answer the core questions of PRISM 2. RUG leads WP4 on preclinical back-translation and biological validation. In addition, RUG will act as the administrative coordinator of the PRISM 2 project with Prof. Dr. Kas as the lead person (project coordinator). RUG contributes to and leads, therefore, also project management and governance (WP1). RUG has extensive expertise and experience with the coordination and administrative roles in major EU-grants, including the previously funded PRISM project.